Clinical Trials · NCT06323174
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Placebo in People With Type 2 Diabetes Treated With Diet and Exercise
- Phase
- Phase 3
- Recruitment status
- Completed
- Sponsor
- Novo Nordisk A/S
- Enrollment
- 189
- Start date
- Mar 2024
- Locations
- 50 sites, 7 countries
- Primary endpoint
- Change in glycated haemoglobin (HbA1c)